CONCERT PHARMACEUTICALS, INC.

Form 4

February 21, 2014

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

January 31, Expires: 2005

OMB APPROVAL

Form 4 or Form 5 obligations **SECURITIES**

Estimated average burden hours per response... 0.5

may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to

Freund John Gordon

Symbol

CONCERT PHARMACEUTICALS,

INC. [CNCE]

(Check all applicable)

(First)

(Street)

(Ctata)

3. Date of Earliest Transaction (Month/Day/Year)

_X__ 10% Owner _X__ Director __ Other (specify Officer (give title

525 UNIVERSITY AVENUE 02/20/2014

(Middle)

(7:-

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Filed(Month/Day/Year) Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

Issuer

below)

PALO ALTO, CA 94301

(City)	(State) (Zip) Table	e I - Non-D	erivative Se	curiti	es Acqı	iired, Disposed of	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired tion(A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		
Common Stock	02/20/2014		С	389,380	A	<u>(1)</u>	421,752	I	See Footnote (2)
Common Stock	02/20/2014		C	530,974	A	<u>(1)</u>	952,726	I	See Footnote (2)
Common Stock	02/20/2014		C	106,194	A	(1)	1,058,920	I	See Footnote
Common Stock	02/20/2014		P	150,000	A	\$ 14	1,208,920	I	See Footnote

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series A Convertible Preferred Stock	(1)	02/20/2014		C		2,200,000	<u>(1)</u>	<u>(3)</u>	Common Stock	389,38
Series B Convertible Preferred Stock	(1)	02/20/2014		С		3,000,000	<u>(1)</u>	(3)	Common Stock	530,97
Series C Convertible Preferred Stock	<u>(1)</u>	02/20/2014		С		600,000	<u>(1)</u>	(3)	Common Stock	106,19

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting owner runner runners	Director	10% Owner	Officer	Other			
Freund John Gordon 525 UNIVERSITY AVENUE PALO ALTO, CA 94301	X	X					

Signatures

JOHN G. FREUND, M.D. Kerensa Kenny, Attorney-in-Fact 02/21/2014

**Signature of Reporting Person Date

Reporting Owners 2

Edgar Filing: CONCERT PHARMACEUTICALS, INC. - Form 4

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A, Series B and Series C Convertible Preferred Stock converted into Common Stock on a 1-for-5.65 basis upon the closing of the issuer's initial public offering without payment of consideration.
- Held by Skyline Venture Partners Qualified Purchaser Fund IV L.P. Dr. John G. Freund is a Managing Member of Skyline Venture
 Management IV, LLC, which is the sole general partner of Skyline Venture Partners Qualified Purchaser Fund IV, L.P., and as such may be deemed to share voting and dispositive power with respect to all shares held by Skyline Venture Partners Qualified Purchaser Fund IV, L.P. Dr. Freund disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.